Patients with IM primary resistance

(n = 20)

Patients with IM secondary resistance (n = 6)

Patients nilotinib-treated

(n = 16)

Patients dasatinib-treated

(n = 10)

patients achieved their CCyR

(n = 10)

patients not achieved their CCyR

(n = 16)

G2677T/A genotypes, n (%)

GG

6 (66.7)

3 (33.3)

6 (66.7)

3 (33.3)

4 (44.4)

5 (55.6)

GT

9 (75)

3 (25)

7 (58.3)

5 (41.7)

5 (41.7)

7 (58.3)

TT

1 (100)

0(0)

1 (100)

0(0)

1 (100)

0(0)

AA

4 (100)

0 (0)

2 (50)

2 (50)

0 (0)

4 (100)

(1236-2677-3435) haplotypes of MDR1 gene, n (%)

CGC

11 (64.7)

6 (35.3)

10 (58.8)

7 (41.2)

8 (47)

9 (53)

CGT

2 (100)

0 (0)

2 (100)

0(0)

2 (50)

2 (50)

CTC

2 (100)

0 (0)

2 (100)

0(0)

0(0)

2 (100)

CAC

5 (100)

0 (0)

2 (40)

3 (60)

0(0)

5 (100)